Healthcare Mergers, Acquisitions & Ventures Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions & Ventures Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
GenVec, Inc.
Interim results from TNFerade study presented at international cancer meeting
November 6th, 2004
GenVec, Inc., (GNVC) announced that interim results from a phase II dose escalation study of TNFerade in esophageal cancer patients were presented at the 16th Symposium on "Molecular Targets and Cancer Therapeutics" at a session of the European Organization for Research and Treatment of Cancer - National Cancer Institute - American Association for Cancer Research (EORTC-NCI-AACR) in Geneva, Switzerland. Patients with resectable esophageal cancer typically receive a combination of radiation and chemotherapy prior to surgical removal of their tumors. The safety and feasibility of adding TNFerade to the standard chemoradiation regimen were assessed in a...
Source: Healthcare Mergers, Acquisitions & Ventures Week (2004-11-06)
|
